POLARIS GROUP |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.5 TWD | +0.60% |
|
-5.06% | -10.71% |
| 2023 | Polaris Group Announces the Appointment of K Evin Wu | CI |
| 2023 | Polaris Group Announces Chief Executive Officer Changes, Effective December 21, 2023 | CI |
| Sales 2021 | 15.04 489.36 | Sales 2022 | 6.44 209.49 | Capitalization | 65.79B 2,141B |
|---|---|---|---|---|---|
| Net income 2021 | -740M -24.08B | Net income 2022 | -1.15B -37.42B | EV / Sales 2021 | 2,838,252,273 x |
| Net cash position 2021 | 5.55B 181B | Net cash position 2022 | 7B 228B | EV / Sales 2022 | 9,131,045,630 x |
| P/E ratio 2021 |
-67.7
x | P/E ratio 2022 |
-56.5
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 36.19% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.60% | ||
| 1 week | -5.06% | ||
| Current month | -5.59% | ||
| 1 month | +10.11% | ||
| 3 months | -8.54% | ||
| 6 months | -6.77% | ||
| Current year | -10.71% |
1 week
66.00
70.00
1 month
61.7078.00
Current year
60.5078.00
1 year
60.50101.00
3 years
44.00232.00
5 years
9.50232.00
10 years
9.50232.00
| Managers | Title | Age | Since |
|---|---|---|---|
J.P. Steve Hsu
CEO | Chief Executive Officer | - | Dec. 20 |
Lan Ying Huang
DFI | Director of Finance/CFO | - | 19-02-28 |
Wei Yuan Lin
COO | Chief Operating Officer | - | 19-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hung Wen Chen
CHM | Chairman | - | 14-11-23 |
Samuel Chen
BRD | Director/Board Member | 73 | 20-02-24 |
John Bomalaski
PRN | Corporate Officer/Principal | - | 06-04-14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | -1.38% | - | |
| 0.00% | 34 M€ | +1.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 67.5 | +0.60% | 848,691 |
| 24-04-17 | 67.1 | +0.75% | 875,467 |
| 24-04-16 | 66.6 | -2.92% | 1,750,030 |
| 24-04-15 | 68.6 | -2.00% | 1,648,901 |
| 24-04-12 | 70 | -1.55% | 1,735,947 |
End-of-day quote Taiwan S.E., April 17, 2024
More quotes
Polaris Group is a Cayman Islands-based biopharmaceutical company, which is engaged in advanced therapies, primarily focusing on metabolic related diseases. The Companyâs drug candidate, Pegargiminase (ADI-PEG 20), is advancing through the biologics license applications (BLA) - enabling stage and clinical development. Pegargiminase (ADI PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Pegargiminase is designed to disrupt cancer cell metabolism, providing a novel approach to treating a range of cancers heavily influenced by metabolic pathways. The Companyâs product pipeline also includes peptide drugs, such as the Semaglutide-related products.
Calendar
2024-05-02
- Annual General Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.71% | 1.55B | |
| -1.82% | 41.35B | |
| +44.25% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- 6550 Stock
